Psychiatry and
Behavioral Sciences

DHA Study

Principal Investigator: J. Wesson Ashford, MD, PhD.
Contact: Stanford/VA Aging Clinical Research Center
(650) 852-3287

[This study is no longer recruiting subjects.]

You may have heard about “Omega-3 fatty acids” in the news or at your grocery store – these nutrients have shown some promising scientific results for heart and brain health. Now scientists want to learn if one omega-3, called DHA, can slow the progression of Alzheimer’s disease (AD).

Participants in the 18-month study will be randomly assigned to one of two groups: 60% will receive DHA and 40% will receive an identical placebo (inactive pill). All participants will be monitored and assessed regularly by a team of doctors and nurses at the research clinic as long as the study lasts. If new information emerges about your health while you are in the study, it will be shared with you and your primary physician.

For more information, please contact the Stanford/VA Aging Clinical Research Center at (650) 852-3287.


Stanford Medicine Resources:

Footer Links: